Pan-cancer profiling of FZD2 as a prognostic biomarker: integrative multi-omics analysis with experimental validation and functional characterization in gastric cancer
FZD2 is widely upregulated in various tumor types, with its expression closely associated with key clinical outcomes, including overall survival, disease-specific survival, disease-free interval, as well as tumor mutations, drug sensitivity, immune cell infiltration, and immunotherapy-related biomarkers such as TMB and MSI. These findings highlight the pivotal role of FZD2 in cancer prognosis and treatment, offering potential for novel therapeutic approaches and the development of personalized medicine strategies in oncology.
Authors
- Chao Quan (ORCID: https://orcid.org/0000-0002-8390-3138)
- Tongtong Qi (ORCID: https://orcid.org/0000-0001-9876-9587)
- Sijiang Zhou (ORCID: https://orcid.org/0000-0001-7014-3670)
- Yongle Li (ORCID: https://orcid.org/0000-0001-9879-0626)
- Da Li (ORCID: https://orcid.org/0000-0002-4895-1185)
- Yu Zhu (ORCID: https://orcid.org/0000-0003-1535-6520)
- Yue Feng (ORCID: https://orcid.org/0009-0006-5668-3025)
- Junqiang Chen (ORCID: https://orcid.org/0000-0001-7022-3099)
- Shengyu Wang (ORCID: https://orcid.org/0000-0002-9774-8319)
Institutions
- Central South University (CN)
- Guangxi Medical University (CN)
- University of Michigan (US)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3389/fphar.2025.1534974
- Citations
- 1
- Primary Topic
- Wnt/β-catenin signaling in development and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81